|
COMMERCE BUSINESS DAILY ISSUE OF AUGUST 26,1997 PSA#1917National Institutes of Health, National Institute of Allergy and
Infectious Diseases, Contract Management Branch, Solar Bldg., Room
3C07, 6003 Executive Blvd. MSC 7610, Bethesda, MD 20892-7610 A -- CANDIDATE HIV VACCINE FOR CLINICAL TRIALS DUE 091097 POC Haynes
Sheppard, Ph.D., FAX: (510) 540-2127, E-Mail: hsheppar@hivnet.fhcrc.org
CANDIDATE HIV VACCINE FOR CLINICAL TRIALS The HIV Vaccine Efficacy
Trials Network (HIVNET), through its Central Laboratory, Public Health
Foundation Enterprises, located in Berkeley, California, is conducting
a market survey to determine the availability and capability of
developers of candidate plasmid DNA HIV vaccines for products to be
used in clinical testing in humans. These products will be considered
for Phase I clinical trials and may eventually be considered for
larger-scale clinical trials. The HIVNET is a research consortium
funded by the National Institute of Allergy and Infectious Diseases,
focusing on clinical trials of HIV prevention strategies in the U.S.
and in developing countries. The HIVNET Central Laboratory is
responsible for coordinating laboratory aspects of prevention research
and has the capacity to procure candidate HIV vaccines for human
trials. To be considered, developers must have: (1) previously
developed candidate plasmid DNA vaccines for use in human trials; (2)
existing relationship with (or be) a manufacturer with experience in
producing candidate plasmid DNA vaccines meeting FDA standards for use
in human studies; and (3) experience with plasmid DNA HIV vaccine
constructs. Interested firms must document their past experience and
technical expertise in each of the above areas. Selected developer(s)
will be asked to develop candidate plasmid DNA HIV vaccines for safety
and immunogenicity testing, with a focus on vaccines for HIV subtypes
other than clade B. This is not a Request for Proposal(RFP). NO RFP is
available and Public Health Foundation Enterprises is not committed to
award a subcontract pursuant to this announcement. Interested firms
should furnish 5 copies of their capability information addressing the
three(3) areas cited above, no later than 4:30 p.m. local time on
September 10, 1997 to Haynes Sheppard, Ph.D., VRDL, 2151 Berkeley Way,
Berkeley, CA 94704, FAX: (510) 540-2127, E-Mail:
hsheppar@hivnet.fhcrc.org. (0234) Loren Data Corp. http://www.ld.com (SYN# 0021 19970826\A-0021.SOL)
A - Research and Development Index Page
|
|